Welcome to our dedicated page for Replimune Group SEC filings (Ticker: REPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through hundreds of pages that detail viral engineering, Phase data, and milestone payments is challenging for any biotech investor. Replimune Group Inc’s filings layer complex clinical trial disclosures onto traditional financial statements, making it tough to pinpoint cash-runway metrics or track when insiders buy shares. Stock Titan’s AI-powered analysis breaks down every section, so understanding Replimune Group Inc SEC documents with AI becomes a five-minute task instead of a full afternoon.
Need the latest Replimune Group Inc quarterly earnings report 10-Q filing? Our real-time feed grabs it from EDGAR seconds after it posts and delivers an executive summary highlighting R&D spend and trial timelines. Wondering about Replimune Group Inc insider trading Form 4 transactions? We tag each filing and send instant alerts on Replimune Group Inc Form 4 insider transactions real-time, helping you gauge management’s confidence. You can also dive into the Replimune Group Inc annual report 10-K simplified to see cash burn projections, or review the Replimune Group Inc proxy statement executive compensation to compare stock-based awards across leadership.
Our platform covers every form—10-K, 10-Q, 8-K, S-3, SC 13G—plus a dedicated stream for Replimune Group Inc 8-K material events explained. Built-in AI models surface key numbers, flag changes in trial enrollment, and translate biotech jargon into plain language. The result: Replimune Group Inc SEC filings explained simply. Use it to perform Replimune Group Inc earnings report filing analysis, monitor Replimune Group Inc executive stock transactions Form 4, and stay ahead of material catalysts—without wading through dense regulatory prose.
Emily Luisa Hill, Chief Financial Officer of Replimune Group, Inc. (REPL), reported the disposition of common stock on 08/15/2025. The filing shows 9,154 shares were sold at $5.37 per share to satisfy tax withholding associated with partial vesting of restricted stock units. After the sale, the reporting person beneficially owned 134,368 shares. The Form 4 notes the sale was executed under the award agreement's irrevocable "sell to cover" provision and was not a discretionary sale by the reporting person. The form was signed by an attorney-in-fact on 08/19/2025.
On 21-Jul-2025 Replimune Group, Inc. (REPL) received a Complete Response Letter (CRL) from the U.S. FDA for its Biologics License Application seeking approval of oncolytic immunotherapy RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The CRL means the agency will not approve the application in its current form and requires additional information before reconsideration. Specific deficiencies and next steps were not disclosed in the 8-K.
The company furnished, but did not “file,” a news release (Exhibit 99.1) under Item 7.01/8.01. No financial statements, earnings impact, or updated guidance were provided. The setback could delay potential commercialization and future revenue for RP1, increasing regulatory uncertainty and development costs.
FAQ
What is the current stock price of Replimune Group (REPL)?
What is the market cap of Replimune Group (REPL)?
